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MINI-ABSTRACT 
 
Clinical remission after unilateral adrenalectomy to treat unilateral primary aldosteronism is 
achieved in less than half of patients. A linear discriminant model with 6 presurgical predictors of 
clinical remission was used to build a 25-point prediction score of postsurgical clinical outcomes. 
The prediction score was integrated into a user-friendly online tool which can be used in a clinical 
setting to differentiate patients who are likely to be clinically cured after surgery from those who 
will need continuous surveillance after surgery due to remnant hypertension.  
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STRUCTURED ABSTRACT 
 
Objective: To develop a prediction model for clinical outcomes after unilateral adrenalectomy for 
unilateral primary aldosteronism.  
Summary Background Data: Unilateral primary aldosteronism is the most common surgically 
curable form of endocrine hypertension. Surgical resection of the dominant overactive adrenal in 
unilateral primary aldosteronism results in complete clinical success with resolution of hypertension 
without antihypertensive medication in less than half of patients with a wide between-center 
variability.  
Methods: A linear discriminant analysis (LDA) model was built using data of 380 patients treated 
by adrenalectomy for unilateral primary aldosteronism to classify post-surgical clinical outcomes. 
The total cohort was then randomly divided into training (280 patients) and test (100 patients) datasets 
to create and validate a score system to predict clinical outcomes. An online tool (PASO [Primary 
Aldosteronism Surgical Outcome] predictor) was developed to facilitate the use of the predictive 
score. 
Results: Six presurgical factors associated with complete clinical success (known duration of 
hypertension, sex, antihypertensive medication dosage, body mass index, target organ damage and 
size of largest nodule at imaging) were selected based on classification performance in the LDA 
model. A 25-point predictive score was built with an optimal cut-off of greater than 16 points 
(accuracy of prediction = 79.2%; specificity = 84.4%; sensitivity = 71.3%) with an area under the 
curve of 0.839.  
Conclusions: The predictive score and the PASO predictor can be used in a clinical setting to 
differentiate patients who are likely to be clinically cured after surgery from those who will need 
continuous surveillance after surgery due to persistent hypertension. 
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INTRODUCTION 
 
Primary aldosteronism (PA) is a frequent cause of endocrine hypertension with prevalence estimates 
ranging from 5-15% in the general population with hypertension1-3 and as high as 20% in patients 
with resistant hypertension4. The overproduction of aldosterone is mainly caused by a unilateral 
aldosterone-producing adenoma or bilateral adrenal hyperplasia which are specifically treated by 
laparoscopic adrenalectomy or with a mineralocorticoid receptor antagonist, respectively5-6. The 
deleterious effects of excessive aldosterone production on cardiovascular, cerebrovascular and renal 
function highlight the importance of an early diagnosis and initiation of specific treatment strategies 
for unilateral and bilateral forms of PA7-10.  
 
The differentiation of unilateral from bilateral forms is achieved by computed tomography (CT) or 
adrenal venous sampling (AVS). AVS is the recommended approach by the Endocrine Society 
Guideline11 because of the lack of specificity and sensitivity of CT12-13. The objective of 
adrenalectomy is to resolve excessive aldosterone production, normalize plasma potassium 
concentrations (if the patient was hypokalemic pre-surgically), and to normalize or at least improve 
the elevated blood pressure which is characteristic of the disorder. Although more than 4 in every 5 
patients with unilateral PA experience a clinical benefit from surgery14, the proportion of patients 
with clinical remission with normalization of blood pressure without the aid of antihypertensive 
medication represents 16-72%14-19.  
 
Several studies have identified presurgical predictors of clinical cure (complete clinical success14) 
such as younger age, female sex, shorter duration of hypertension before surgery, number of 
antihypertensive drugs, low serum potassium and high urinary aldosterone levels14,18,20,21.  
A prediction score for the resolution of hypertension after surgery has been developed17 which also 
performed well in a patient cohort from Japan22 but not in a French population23. The aldosteronoma 
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resolution score is based on a points system to predict 3 levels (low, medium, high) of likelihood of 
clinical cure. A positive predictive value of 75.0% (9 of 12 patients) was achieved with the validation 
dataset at the high likelihood level albeit with a low sensitivity of 31.0% (9 of 29 patients with clinical 
cure were accurately predicted). The negative predictive value of the lowest likelihood score was 
72.4% (21 of 29 patients) with a specificity of 55.3% (21 of 38 patients)17. 
 
We developed a prediction score (PASO [Primary Aldosteronism Surgical Outcome] score) for 
complete clinical success after adrenalectomy for unilateral PA using patient data from a large 
multicenter cohort with outcomes assessed in accordance with a standardized set of criteria14,24. The 
PASO score requires input of 6 presurgical variables and can be calculated either manually or with 
an online tool (PASO predictor) to facilitate the use of the prediction score in the clinical setting. To 
provide additional information on the probability of a complete, partial or absent clinical outcome, 
the PASO predictor also computes the proportion of patients from the multicenter cohort in each 
outcome group. The PASO score can be used by clinicians for the management of patient expectations 
of post-surgical clinical outcomes and to identify which patients will need close follow up due to 
persistent hypertension. 
 
METHODS 
 
Study Cohort 
Patient data from the PASO study14 were used to train and validate a predictive model for clinical 
outcomes after adrenalectomy for unilateral PA. Variables associated with complete clinical success 
were selected from unadjusted and adjusted logistic regression models (Table 1) and all patients 
without missing values for these variables were included for further analyses (n= 380). The clinical 
characteristics of the study cohort are reported in Table 2.  These patients were a subset of 8 of the 
12 centers that participated to the PASO study (Berlin [n=29], Brisbane [n=44], Munich [n=98], 
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Nijmegen [n=8], Yokohama City [n=61], Sendai [n=63], Torino [n=75] and Warsaw [n=2]). The 
study cohort was randomly divided into a training dataset (n= 280) to develop the predictive model 
and a test dataset (n= 100) to validate the model (see Supplemental Digital Content Table 1, for a 
comparison of clinical parameters of patients in the training and test datasets). Written informed 
consent was obtained in accordance with the ethical standards of all institutions except in Yokohama 
City because written consent for the analysis of patient data is not required in Japan. 
  
PA was diagnosed in accordance with the US Endocrine Society or the Japan Endocrine 
Guideline11,25. Unilateral PA was differentiated from bilateral PA by adrenal venous sampling in all 
patients before adrenalectomy. Clinical and biochemical outcomes were classified as complete, 
partial and absent success, and were evaluated in accordance with the PASO consensus14. Clinical 
outcomes were defined by blood pressure measurements and antihypertensive medication dosages. 
Patients with complete clinical success comprise those with normalized blood pressure levels without 
the use of antihypertensive medication after surgery. Biochemical outcomes were defined according 
to serum potassium concentrations and the aldosterone-to-renin ratio (ARR). Patients with 
normalization of hypokalemia (if present pre-surgery) and normalization of the ARR were classified 
as complete biochemical success. Further details on the criteria defining clinical and biochemical 
outcomes are described elsewhere14. 
 
Linear Discriminant Analysis  
Linear discriminant analysis (LDA) was performed using MATLAB R2017b software on the 
combined cohort (n = 380 patients) employing linear combinations of variables to maximize the 
separation between groups by increasing precision estimates by variance reduction26,27. LDA models 
have been widely exploited in the context of prediction modelling for clinical research as described 
previously28-32. In the model used herein, the algorithm computes a set of coefficients for linear 
combination with each variable to predict clinical outcome. An estimation of clinical outcome is 
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derived from the following equation: Complete clinical success = LDAcoeff1*Variable1 + 
LDAcoeff2*Variable2 + … + LDAcoeffn*Variablen > 0.2082. LDA coefficients are reported in 
Supplemental Digital Content Table 2, whereas normalized coefficients are represented in Figure 1C. 
The combination of variables which gave the best accuracy of classification of complete clinical 
success versus partial and absent success combined was selected by the algorithm and the 
performance of the LDA model was assessed by 10-fold cross validation. The 10-fold cross validation 
analysis randomly divides the cohort into 10 subgroups. The model is trained with the first 9 
subgroups, the remaining group is used for validation. The validation group is then changed and 
accordingly the training groups. The process is repeated a total of 10 times with the validation group 
rotating at each round and the remaining subgroups used for model training. 
 
Prediction score 
The 6 variables selected by the LDA model were used to develop a 25-point prediction score (PASO 
score); variables were categorized using the MATLAB R2017b software algorithm and cut-offs were 
automatically derived to achieve the best accuracy; points were assigned on the basis of discriminant 
analysis normalized coefficients and ORs from the adjusted regression analyses.  
The PASO score was generated using a training dataset (n= 280) and validated on the test dataset (n= 
100). A receiver operating characteristic (ROC) curve was used to assess the area under the curve 
(AUC) and the best cut-off to discriminate complete versus (partial + absent) clinical success after 
adrenalectomy was automatically defined by the software (MATLAB R2017b) algorithm and 
confirmed by evaluation of the Youden Index (J = sensitivity + specificity - 1). An online tool was 
developed that automatically calculates the defined daily dose (DDD), the score and the predicted 
clinical outcome (PASO predictor available at https://github.com/ABurrello/PASO-
Predictor/raw/master/00%20-%20PASO%20Predictor.xlsm  
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Statistical Analyses 
IBM SPSS Statistics 24 (IBM Corp. Armonk, New York, USA) was used for statistical analyses. The 
normally distributed variable (BMI) is expressed as the mean ± SD and analyzed by a one-way 
ANOVA test; non-normally distributed variables (duration of hypertension, DDD, nodule diameter) 
are expressed as medians and interquartile range and analyzed using the Mann-Whitney’s test. 
Categorical variables (sex, target organ damage) are expressed as absolute numbers and proportions 
(%) and analyzed by a chi square test. Unadjusted and adjusted logistic regression analyses were used 
to determine odds ratios (ORs) for the 6 variables selected by the LDA on the combined cohort (n= 
380 patients). An OR greater than 1 indicates an increased likelihood of complete clinical success, an 
OR less than 1, a decreased likelihood. Correlations were evaluated by a Pearson test. A P-value of 
less than 0.05 was considered significant.  
 
RESULTS 
 
LDA prediction model 
The cohort included 380 surgically-treated patients for unilateral PA with complete datasets (see 
Table 2 for patient characteristics). Complete clinical success was achieved in 150 of the 380 patients 
(39.5%), partial or absent clinical success in 173 (45.5%) and 57 patients (15%), respectively. 
Complete biochemical success was achieved in 357 of 380 (93.9%) patients, with a further 16 (5.2%) 
and 7 (1.8%) patients displaying partial or absent biochemical success after surgery, respectively. 
Using unadjusted univariate and adjusted multivariate analyses, we selected the variables with the 
strongest association with complete clinical success (Table 1). In the unadjusted analysis, all selected 
variables were significantly associated with complete clinical success (P < 0.001) except largest 
nodule size. In the adjusted model, duration of hypertension (OR 0.99 per month; CI 95% 0.98-0.99; 
P < 0.001), sex (reference female; OR 2.91; 95% CI 1.74-4.86; P = < 0.001), DDD (OR 0.81 per unit 
increase; 95% CI 0.72-0.92; P = 0.001), target organ damage (reference presence; OR 2.84; 95% CI 
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1.69-4.78; P < 0.001) and largest nodule at imaging (OR 1.03 per mm; 95% CI 1.01-1.06; P = 0.048) 
were all confirmed as independent predictors. 
 
The combination of variables with the best accuracy of prediction of complete clinical success versus 
(partial + absent) success was used in the LDA model. The variables were known duration of 
hypertension (months), sex (female/male), BMI (Kg/m2), antihypertensive medication (defined by 
DDD), presence of target organ damage (left ventricular hypertrophy and/or microalbuminuria) and 
largest nodule size at imaging (diameter, mm). Known duration of hypertension had a greater 
predictive performance than age (a correlated confounding variable) and was selected for inclusion. 
The linear combination of variables included in the LDA is shown in the canonical plot (Figure 1A). 
Each point represents a patient and the distribution of clinical outcomes indicates that the model can 
distinguish complete from partial + absent clinical success combined whereas patients with partial 
clinical success cannot be differentiated from those with absent success.  
 
The LDA model correctly predicted the outcomes of 293 of 380 patients (77.1% accuracy) with a 
sensitivity of 69.3% and a specificity of 82.2% (Figure 1B). In detail, 104 of 150 and 189 of 230 
patients were correctly assigned to the complete and the partial + absent clinical success groups, 
respectively. To exclude overfitting and to assess how the prediction could generalize in an 
independent cohort, the LDA model was validated by 10-fold cross validation analysis that confirmed 
a high predictive performance with an accuracy of 75.3% (with cross validation), compared with 
77.1% (with the LDA model), thus excluding any risk of bias. In the LDA model, the strongest 
predictor of complete clinical success was known duration of hypertension (LDA normalized 
coefficient equal to 1.0), followed by antihypertensive medication and largest nodule size at imaging 
(0.8 and 0.5, respectively; Figure 1C and Supplemental Digital Content Table 2 that shows the 
normalized LDA coefficients for each of the 6 variables). 
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PASO score 
Patients included in the LDA model (n = 380) were randomly assigned to a training dataset (n = 280) 
and a test dataset (n = 100). There were no differences in clinical outcomes or in any of the 6 variables 
used in the LDA model between the 2 cohorts (see Supplemental Digital Content Table 1 for a 
comparison of the training and test datasets). 
 
The 6 variables selected by the LDA model were used to develop a 25-point score (the PASO score) 
on the training dataset. Figures 2A and 2C shows variables and points assigned to each category. The 
best cut-off was identified by the ROC curve (Figure 2B); the area under the curve was 0.839 (95% 
CI 0.798-0.881). In the training dataset, a cut-off greater than 16 correctly predicted complete clinical 
success in 78 of 110 patients, whereas a cut-off equal or lower than 16 predicted partial and absent 
clinical success combined in 150 of 170 patients (sensitivity 70.9% and specificity 88.2%). The 
overall accuracy of the model was 81.4% (Figure 2D). With validation of the score using the test 
dataset, 73 of 100 patients were correctly classified (accuracy 73%). The predictive performance on 
the combined cohort was still higher than the LDA model, with correct classification of 301 of 380 
patients (accuracy, 79.2%; sensitivity, 71.3% and specificity, 84.4%) (Figure 2D). Positive and 
negative predictive values were respectively 74.8% and 81.6% (Table 3). The difference between the 
accuracy of the PASO score in the training dataset and in the test dataset (81.4% and 73.0%, 
respectively) revealed a modest bias due to the effect of overfitting (best performance of the model 
in the cohort in which it is trained), which was expected and did not affect the reliability of the model. 
 
As expected, the PASO score was directly correlated with the proportion of patients with complete 
clinical success (R = 0.940; P < 0.001) (Figure 3). Supplemental Digital Content Table 3 shows 
patients in the combined cohort stratified for clinical outcomes and for PASO score. Patients with a 
score of 24.1-25 all had complete clinical success after surgery (n = 9); a single patient with a score 
of 0-2.0 had partial clinical success. For patients with a PASO score equal to or greater than 20, 
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complete clinical success was correctly predicted in 58 of 69 patients (positive predictive value 
84.1%; Table 3). For patients with a PASO score less than 10, partial and absent clinical success 
combined was correctly predicted in 72 of 77 patients (negative predictive value 93.5%; Table 3). 
 
The LDA model was adapted to predict all patients with a potential clinical benefit after surgery. For 
this we attempted to develop 2 additional models: (complete + partial) versus absent clinical success 
and complete versus partial versus absent clinical success. For the prediction of (complete + partial) 
versus absent clinical success, we achieved an accuracy of 85.3% and 71.8% for the LDA model and 
the PASO score (on the combined cohort), respectively but this was achieved with very low 
specificity (Supplemental Digital Content Table 4). For the prediction of complete versus partial 
versus absent clinical success, the model attained moderate accuracy (63.4% for the LDA model and 
55.3% for the PASO score on the combined cohort; Supplemental Digital Content Table 5). The low 
performance of these two additional models is because of the difficulty in distinguishing patients with 
partial versus absent clinical success due to the relatively low number of patients in the absent clinical 
success group (44 in the training dataset and 13 in the test dataset) and to the similarity of the clinical 
characteristics of patients in the absent and partial subgroups for 5 of the 6 variables used in the 
predictive model (they differed only for antihypertensive medication dosage, a criteria used for the 
definition of clinical outcomes by the PASO consensus14; Supplemental Digital Content Table 6). 
 
Finally, we assessed the generalizability of our model for each center included in the analysis. We 
found no significant differences for the accuracies of the LDA model and the PASO score (P = 0.284 
and P = 0.188, respectively) applied to patients stratified by center (Supplemental Digital Content 
Table 7). 
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DISCUSSION 
 
The optimal treatment for unilateral forms of PA is laparoscopic adrenalectomy which should remove 
the source of aldosterone overproduction and potentially cure the disorder. There is a wide variability 
in clinical outcomes with usually less than half of patients in a given center achieving complete 
clinical success after surgery with normalization of blood pressure without the aid of antihypertensive 
medication14,17,18,33. A substantial proportion of patients (35-66%) have a partial clinical response to 
adrenalectomy (partial clinical success) and the absence of clinical benefit (absent clinical success) 
is found in 0-32%14. Several factors influence clinical outcomes after adrenalectomy such as sex, age, 
concurrent primary hypertension and long-standing PA14,18,20,21,34. Presurgical factors associated with 
clinical outcomes can be exploited to develop prediction scores to provide objective measures of 
clinical outcomes and, if reliable, used to counsel patients on the probability of a surgical cure versus 
a lifetime of antihypertensive medication. 
 
In this study we developed a prediction tool, the PASO predictor, for clinicians to differentiate 
patients with unilateral PA with a complete clinical response to unilateral adrenalectomy from those 
with a partial and absent response combined. Although not achieving clinical cure, patients with 
partial clinical success after unilateral adrenalectomy obtain substantial clinical benefits but will need 
continuous surveillance after surgery due to remnant hypertension. The PASO predictor may help 
clinicians evaluate the benefits of surgery and inform patients on their expected post-surgical 
outcomes as well as identifying which patients require close follow up.   
 
A prediction score (Aldosteronoma Resolution Score) was developed previously based on a points 
system using 4 readily available variables (number of antihypertensive drugs, duration of 
hypertension, sex and BMI)17. We developed an improved prediction score (PASO score) using 
patient data from a multicenter international cohort. Applying the PASO score to the combined 
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dataset in the present study gave a positive predictive value of 84.1% (58 of 69 patients) using the 
highest level for likelihood of complete clinical success (≥ 20 points) and a negative predictive value 
of 93.5% (72 of 77 patients) for the lowest likelihood level (≥ 10 points). This compares favorably 
with the previously published aldosteronoma resolution score which, in the total dataset, had a 
positive predictive value of 80.0% (28 of 35 patients) for the highest likelihood of clinical cure (4-5 
points) and a negative predictive value of 86.3% (63 of 73 patients) for the lowest likelihood level 
(0-1 points)17. Our validation of the score indicated an accuracy of prediction of 73.0% (72.5% 
sensitivity and 73.3% specificity) compared with an accuracy of 65.7% with the validation dataset of 
the aldosteronoma score (sensitivity, 31.0%; specificity, 92.1%).  
 
Our score is more complex than the aldosteronoma resolution score. The LDA model identified 2 
variables (largest nodule size at imaging and target organ damage evaluated by microalbuminuria 
and/or left ventricular hypertrophy) in addition to the same 4 variables used in the aldosteronoma 
resolution prediction score. These 2 variables were included because target organ damage displayed 
a better predictive performance than BMI; and nodule size performed better than both target organ 
damage and sex. Adrenal CT or MRI and target organ damage should be evaluated in all patients with 
PA because the possibility of an aldosterone-producing carcinoma requires exclusion by imaging11 
and the routine assessment of microalbuminuria and left ventricular hypertrophy is recommended in 
all patients with hypertension35. Evaluation of target organ damage to the kidneys and heart is 
particularly relevant in patients with PA because of their increased risk (which can be reversed with 
appropriate treatment) relative to patients with primary hypertension7,8,10,36-38.  
 
A prediction score that separates partial from an absent clinical outcome would also be useful because 
patients with a partial clinical outcome derive clinical benefits from surgery, potentially attaining a 
substantial improvement in hypertension status or antihypertensive drug requirements (possibly 
achieving normalization of blood pressure although with the aid of antihypertensive medication). The 
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LDA model described herein could not separate the partial from absent clinical success groups. 
However, to partially address this need, the PASO predictor indicates the probability of achieving 
each clinical outcome by calculating the proportion of patients with complete, partial and absent 
clinical success for the PASO score based on the clinical outcomes of the total cohort. 
 
The strengths of our study include the multicenter inclusion of a large number of patients from a wide 
geographical spread and the high performance of the PASO score using a validation test which 
indicated the general applicability of the score. We also developed a user-friendly online tool to 
calculate the PASO score which automatically converts antihypertensive medication dosages to 
DDDs (a standardized measure of medication) and predicts the likelihood of complete clinical success 
after adrenalectomy as well as those patients in the partial and absent clinical success groups 
combined that require close post-surgical follow up. A potential limitation of the prediction score is 
the increased number of input variables relative to previous models with the requirement of adrenal 
imaging data and assessment of target organ damage which are nonetheless widely considered 
essential evaluations in patients with PA. Another limitation is the inability of the prediction score to 
differentiate patients with a clinical benefit after surgery (complete + partial from absent or complete 
versus partial versus absent clinical success), but the PASO predictor calculates the probability of 
each clinical outcome at any given PASO score which, although not a prediction score, can be used 
to advice patients on their likely clinical outcomes. 
 
In conclusion, we developed a score system based on presurgical factors, integrated into an online 
tool, to reliably predict complete clinical success after adrenalectomy and to guide the clinical 
management of patients with PA.  
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Table 1 – Predictive variables for complete clinical success after adrenalectomy 
Variable (n = 380) 
Unadjusted Analysis Adjusted Analysis 
Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value 
Duration of hypertension (months) 0.99 (0.98 – 0.99) < 0.001 0.99 (0.98-0.99) < 0.001 
Sex (Female, %) 4.03 (2.60 – 6.25) < 0.001 2.91 (1.74-4.86) < 0.001 
BMI (kg/m2) 0.92 (0.88 – 0.96) < 0.001 1.00 (0.95-1.05) 0.996 
AntiHT medication (DDD) 0.71 (0.63 – 0.80) < 0.001 0.81 (0.72-0.92) 0.001 
Target organ damage (absence, %) 3.31 (2.14 – 5.13) < 0.001 2.84 (1.69-4.78) < 0.001 
Largest nodule at imaging (mm) 1.02 (0.99 – 1.05) 0.061 1.03 (1.01-1.06) 0.048 
 
Logistic regression analyses were performed to assess the odds ratios (OR) and 95% confidence 
intervals (CI) for the six variables selected by the LDA model. The unadjusted univariate and adjusted 
multivariate ORs are shown as indicated. An OR greater than 1 indicates an increased likelihood of 
complete clinical success (clinical cure) and an OR less than 1 a decreased likelihood. Patient data 
from the total cohort (n = 380) were included in the models. BMI (body mass index), DDD (defined 
daily dose), duration of hypertension and largest nodule at imaging were treated as continuous 
variables; sex and target organ damage were treated as categorical variables. AntiHT medication, 
antihypertensive medication. 
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in 
adults (https://www.whocc.no/atc_ddd_index/). 
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Table 2. Patient characteristics of study cohort 
Variables Cohort (N = 380) 
Age at surgery (years) 50.5 ± 11.2 
Sex (Female; %) 184 (48.4) 
BMI (kg/m2) 26.9 ± 5.2 
Systolic blood pressure (mmHg) 153 ± 23.1 
Diastolic blood pressure (mmHg) 93 ± 14.2 
Duration of hypertension (months) 99.5 [47.3-183.0] 
AntiHT medication (DDD) 2.5 [1.5-4.3] 
Plasma aldosterone (pmol/L) 881 [569-1430.5] 
DRC (mU/L) 5.0 [3.2-12.5] 
PRA (pmol/L) 2.6 [1.3-5.1] 
Lowest serum potassium (mmol/L) 3.0 [2.7-3.5] 
eGFR (mL/min) 85.0 [70.8-95.0] 
Target organ damage (absence; %) 241 (63.4) 
Largest nodule at imaging (mm) 13.5 [9.0-17.0] 
Clinical Outcome 
Complete 
Partial 
Absent 
 
150 (39.5) 
173 (45.5) 
57 (15.0) 
Biochemical Outcome  
Complete  
Partial 
Absent 
 
357 (94.0) 
16 (4.2) 
7 (1.8) 
 
Clinical characteristics of patients included in the analysis. AntiHT medication, antihypertensive 
medication; BMI, body mass index; DDD, defined daily dose; DRC, direct renin concentration; 
eGFR, glomerular filtration rate; PRA, plasma renin activity. Age at surgery, BMI, systolic and 
diastolic blood pressure are expressed as the mean ± SD; duration of hypertension, DDD, plasma 
aldosterone, DRC, PRA, lowest serum potassium, eGFR and largest nodule at imaging are expressed 
as medians and interquartile range; sex, target organ damage, clinical and biochemical outcome are 
expressed as absolute numbers and proportions (%). 
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in 
adults (https://www.whocc.no/atc_ddd_index/). 
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Table 3. Predictive performance of the LDA model and the PASO score  
Model Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) 
LDA 69.3 (104/150) 82.2 (189/230) 71.7 (104/145) 80.4 (189/235) 77.1 (293/380) 
≥ 20 38.7 (58/150) 95.2 (219/230) 84.1 (58/69) 70.4 (219/311) 72.9 (277/380) 
> 16 71.3 (107/150) 84.4 (194/230) 74.8 (107/143) 81.6 (194/237) 79.2 (301/380) 
≥ 10 96.7 (145/150) 31.3 (72/230) 47.9 (145/303) 93.5 (72/77) 57.1 (217/380) 
 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy are shown for the 
LDA model and the PASO score (with different cut-offs) in the combined cohort (n = 380). The optimal cut-off is >16 
points which is derived from the ROC of the LDA model. A score ≥20 points gives the highest proportion of true positive 
results (84.1%) and a score ≥ 10 the highest proportion of true negative results (93.5%) for complete clinical success 
(shown in bold). 
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Figure 1 - Linear discriminant analysis model to predict clinical outcomes after unilateral 
adrenalectomy  
The linear discriminant analysis (LDA) model included the 6 variables that gave the best 
classification of clinical outcomes for the combined cohort (n= 380 patients). Panel A, canonical plot 
showing the clinical outcome of each patient in the combined cohort. Each patient is indicated by a 
point and outcomes are represented by color (complete, green; partial, orange; absent, red). The 
canonical axes of the plot (canonical 1 and canonical 2) are calculated by the LDA from weighted 
linear combinations of the 6 variables included in the model to maximize separation between the 3 
clinical outcome groups. The crosses indicate the means of (canonical 1; canonical 2) for each clinical 
outcome, the ellipses include patients with a linear combination coefficient that falls within the mean 
± SD (canonical 1 ± SD; canonical 2 ± SD). Panel B, real and predicted clinical outcomes, the 
accuracy, sensitivity, specificity and 10-fold cross validation of the LDA model. Panel C, the 
normalized coefficients for each variable included in the LDA model. AntiHT medication, 
antihypertensive medication; BMI, body mass index, HTN, hypertension. 
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Figure 2 - PASO score to predict clinical outcomes after unilateral adrenalectomy  
The LDA model and adjusted linear regression analysis were used to assign prediction points to each 
variable according to stratification level. The model was trained using a subset of patients (training 
set, n = 280 patients) to optimize the prediction score system. Panel A, shows the included variables 
and final points system used for the PASO score. Panel B, receiver operating characteristic (ROC) 
curve used to identify the best cut-off from the PASO prediction (greater than 16 score points) using 
the combined cohort (n = 380). AUC, Area Under the Curve. Panel C, illustration of cut-offs and 
assigned points for each variable after categorization; outcomes are represented by color (complete, 
green; partial, orange; absent, red); the bars indicate the median and interquartile range for each 
outcome. Categorization was performed using the MATLAB R2017b software algorithm and cut-
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offs were automatically derived. Points were assigned to achieve the best accuracy based on 
normalized LDA coefficients (see Supplemental Digital Content Table 2 and Figure 1C), ORs from 
regression analyses (Table 1) and from the level of separation of complete clinical success from other 
outcome groups. Panel D, the real and predicted clinical outcomes, accuracy, sensitivity and 
specificity for the training dataset (n = 280), test dataset (n = 100) and the combined cohort (n = 380). 
AntiHT medication, antihypertensive medication; BMI, body mass index; DDD, define daily dose; 
LVH, left ventricular hypertrophy; MA, micro-albuminuria.  
A downloadable PASO predictor is available at https://github.com/ABurrello/PASO-
Predictor/raw/master/00%20-%20PASO%20Predictor.xlsm 
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Figure 3 - Stratification of clinical outcomes after unilateral adrenalectomy by PASO prediction 
score 
The histogram indicates the performance of the PASO predictor on the combined cohort (n= 380 
patients) and shows the proportion of patients (y-axis, %) in each clinical success category (complete, 
green; partial, orange; absent, red) stratified by the PASO score (x-axis). The total number of patients 
(N) in each PASO score level is indicted. Supplemental Digital Content Table 3 shows the actual 
numbers and proportion of patients in each stratification level. 
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Supplemental Digital Content Table 1  
Characteristics of patients with unilateral primary aldosteronism included in the training and 
test datasets 
Variable 
Combined cohort 
(n = 380) 
Training Dataset 
(n = 280) 
Test Dataset 
(n = 100) 
P-
value 
Clinical  
Outcome 
Complete 150 (39.5) 110 (39.3) 40 (40.0) 
0.804 Partial 173 (45.5) 126 (45.0) 47 (47.0) 
Absent 57 (15.0) 44 (15.7) 13 (13.0) 
Biochemical 
Outcome 
Complete 357 (94.0) 263 (93.9) 94 (94.0)  
Partial 16 (4.2) 12 (4.3) 4 (4.0) 0.984 
Absent 7 (1.8) 5 (1.8) 2 (2.0)  
Duration of hypertension (months) 99.5 [47.3-183.0] 109.5 [47.0-187.8] 87.5 [48.0-162.0] 0.384 
Sex (Female; %) 184 (48.4) 133 (47.5) 51 (51.0) 0.548 
BMI (kg/m2) 26.9 ± 5.2 26.8 ± 5.0 26.9 ± 5.6 0.880 
AntiHT medication (DDD) 2.5 [1.5-4.3] 2.3 [1.5-4.5] 3.0 [1.4-4.2] 0.906 
Target organ damage (absence; %) 241 (63.4) 179 (63.9) 62 (62.0) 0.731 
Largest nodule at imaging (mm) 13.5 [9.0-17.0] 13.0 [9.0-17.0] 14.0 [9.0-17.0] 0.789 
 
From the combined cohort (n = 380), patients were randomly assigned to the training dataset (n = 
280) or the test dataset (n = 100). Patients did not differ for any of the variables included in the model. 
AntiHT medication, antihypertensive medication; BMI, Body Mass Index; DDD, defined daily dose.  
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in 
adults (https://www.whocc.no/atc_ddd_index/). 
 
 
  
 28 
Supplemental Digital Content Table 2  
LDA coefficients for the prediction of clinical outcomes 
Variable LDA Coefficient Normalized Coefficient 
Duration of hypertension (months) -0.007 1.00 
Sex (Female; %) 1.198 0.31 
BMI (kg/m2) -0.010 0.08 
AntiHT medication (DDD) -0.207 0.80 
Target organ damage (absence; %) -1.110 0.28 
Largest nodule at imaging (mm) 0.028 0.50 
 
LDA coefficients and normalized coefficients. LDA coefficients can be used in combination with 
each single variable to predict patient outcome. Each variable is multiplied by its corresponding LDA 
coefficient and the adjusted coefficients are summed to derive value X according the following 
equation: Complete clinical success = LDAcoeff1*Variable1 + LDAcoeff2*Variable2 + … + 
LDAcoeffn*Variablen > 0.2082. If the value of X is more than the given cut-off (0.2082) then complete 
clinical success is predicted. AntiHT medication, antihypertensive medication; BMI, body mass 
index; DDD, defined daily dose.  
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in 
adults (https://www.whocc.no/atc_ddd_index/). 
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Supplemental Digital Content Table 3  
Distribution of patients with unilateral primary aldosteronism stratified by clinical success 
after adrenalectomy and PASO score 
Score 
Total 
(n) 
Absent Partial Complete 
(n) (%) (n) (%) (n) (%) 
0.0-2.0 1 0 0.0 1 100.0 0 0.0 
2.1-4.0 9 0 0.0 8 88.9 1 11.1 
4.1-6.0 14 2 14.3 11 78.6 1 7.1 
6.1-8.0 31 12 38.7 18 58.1 1 3.2 
8.1-10.0 31 4 12.9 22 71.0 5 16.1 
10.1-12.0 55 10 18.2 37 67.3 8 14.5 
12.1-14.0 55 16 29.1 28 50.9 11 20.0 
14.1-16.0 41 5 12.2 20 48.8 16 39.0 
16.1-18.0 57 4 7.0 15 26.3 38 66.7 
18.1-20.0 38 3 7.9 7 18.4 28 73.7 
20.1-22.0 25 1 4.0 5 20.0 19 76.0 
22.1-24.0 14 0 0.0 1 7.1 13 92.9 
24.1-25.0 9 0 0.0 0 0.0 9 100.0 
Total 380 57 N.A. 173 N.A. 150 N.A. 
 
The number (n) and proportion (%) of patients stratified for clinical success (complete, partial, absent) 
and PASO score is shown in the combined cohort (n = 380). N.A., not applicable.  
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Supplemental Digital Content Table 4  
PASO score to predict clinical outcomes after unilateral adrenalectomy: complete + partial 
versus absent clinical success 
(A) 
Clinical Outcome 
[LDA Model] 
Predicted Accuracy (%) 85.3 
Complete + 
Partial Absent Sensitivity (%) 99.7 
R
ea
l Complete + Partial 322 1 Specificity (%) 3.5 
Absent 55 2 10K-Cross-validation (%) 84.7 
 
(B) 
PASO Score Accuracy Predicted Clinical Outcome Performance 
R
ea
l C
lin
ic
al
 O
ut
co
m
e 
Training dataset (n = 280) Complete + Partial Absent Accuracy (%) 72.9 
Complete + Partial 187 49 Sensitivity (%) 79.2 
Absent 27 17 Specificity (%) 38.6 
Test dataset (n = 100) Complete + Partial Absent Accuracy (%) 69.0 
Complete + Partial 68 19 Sensitivity (%) 78.2 
Absent 12 1 Specificity (%) 7.7 
Combined Cohort (n = 380) Complete + Partial Absent Accuracy (%) 71.8 
Complete + Partial 255 68 Sensitivity (%) 78.9 
Absent 39 18 Specificity (%) 31.6 
 
Panel A, shows the real and predicted clinical outcomes, the accuracy, sensitivity, specificity and 10-
fold cross validation of the LDA model. 
Panel B, shows the real and predicted clinical outcomes, accuracy, sensitivity and specificity for the 
training dataset (n = 280), test dataset (n = 180) and the combined cohort (n = 380) for the PASO 
score. A cut-off of greater than 10 points identifies patients with complete + partial clinical success. 
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Supplemental Digital Content Table 5  
PASO score to predict clinical outcomes after unilateral adrenalectomy: complete versus 
partial versus absent clinical success. 
 (A) 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
Panel A, shows the real and predicted clinical outcomes, the accuracy, sensitivity, specificity and 10-
fold cross validation of the LDA model. 
Panel B, shows the real and predicted clinical outcomes, accuracy, sensitivity and specificity for the 
training dataset (n = 280), test dataset (n = 180) and the combined cohort (n = 380) for the PASO 
score. A cut-off of > 16 points identifies patients with complete clinical success; a cut-off of > 10 and 
≤ 16 identifies patients with partial clinical success; a cut-off of ≤ 10 identifies patients with absent 
clinical success.  
Clinical Outcome 
[LDA Model] 
Predicted Accuracy 63.4% / Cross-Validation 61.6% 
Complete  Partial Absent Sensitivity (%) Specificity (%) 
R
ea
l 
Complete 113 35 2 75.3 55.7 
Partial 44 124 5 71.7 56.5 
Absent 17 36 4 7.0 73.4 
PASO Score Accuracy Predicted Clinical Outcome 
Performance 
R
ea
l C
lin
ic
al
 O
ut
co
m
e 
 Complete Partial Absent 
Training dataset (n = 280)  Accuracy 57.5% Sensitivity  Specificity  
Complete 78 27 5 70.9 48.8 
Partial 16 66 44 52.4 61.7 
Absent 4 23 17 38.6 61.0 
Test dataset (n = 100)  Accuracy 49.0% Sensitivity  Specificity  
Complete 29 8 3 72.5 33.3 
Partial 12 19 16 40.4 56.6 
Absent 4 8 1 7.7 55.2 
Combined Cohort (n = 380)  Accuracy 55.3% Sensitivity  Specificity  
Complete 107 35 8 71.3 44.8 
Partial 28 85 60 49.1 60.4 
 Absent 8 31 18 31.6 59.4 
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Supplemental Digital Content Table 6  
Characteristics of patients stratified for clinical outcome 
 
 
 
 
 
 
 
The P-value is referred to the comparison between patients with a partial versus absent clinical 
success. AntiHT medication, antihypertensive medication; BMI, Body Mass Index; DDD, defined 
daily dose. The DDD is the assumed average maintenance dose per day for a drug used for its main 
indication in adults (https://www.whocc.no/atc_ddd_index/). 
  
Clinical Outcome Complete (N = 150) 
*Partial 
(N = 173) 
*Absent 
(N = 57) 
*P-value 
(Partial vs 
Absent) 
Duration of hypertension 
(months) 
61.0  
[24.0-108.0] 
134.0 
[73.5-234.0] 
138.0  
[57.5-241.0] 0.705 
Sex (Female, %) 103 (68.7) 67 (38.7) 14 (24.6) 0.056 
BMI (kg/m2) 25.6 ± 5.3 27.4 ± 4.6 28.7 ± 6.0 0.083 
AntiHT medication (DDD) 1.8  [1.0-3.0] 
3.6  
[2.1-5.5] 
2.3  
[1.5-3.5] 0.001 
Target organ damage  
(absence,  %) 80 (53.3) 42 (24.3) 17 (29.8) 0.484 
Largest nodule at CT (mm) 15.0  [10.0-18.0] 
12.0  
[9.0-16.0] 
10  
[6.5-17.0] 0.133 
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Supplemental Digital Content Table 7  
LDA model and PASO predictor performances for the prediction of clinical outcomes of 
patients stratified by recruitment center 
 
Center N 
Accuracy (%) 
LDA model PASO predictor 
Berlin 29 65.5 62.1 
Brisbane 44 68.2 75 
Munich 98 79.6 82.7 
Nijmegen 8 62.5 62.5 
Yokohama City 61 83.6 83.6 
Sendai 63 76.2 79.4 
Torino 75 81.3 82.7 
Warsaw 2 50.0 50.0 
 
 
Our model generalizes to patients stratified by center (no significant differences among accuracies 
for the LDA model and PASO predictor, respectively, P = 0.284 and P = 0.188), thus excluding bias 
due to center heterogeneity. 
 
 
 
